Earnings Releases·Nov 5, 2026, 7:40 AM ET

Lantheus — Third Quarter 2026 Earnings Summary

Worldwide revenue increased 1.5% year-over-year to $389.9 million; GAAP net income declined 19.4% to $22.4 million, while adjusted net income rose 34.3% to $115.1 million.
The company entered a definitive agreement to merge with Curium in an all-cash transaction valued up to $8.0 billion, offering $102.50 per share plus up to $12.00 in contingent value rights.
Full-year 2026 financial guidance has been suspended due to the pending merger, and the company will not host a conference call for these results.
Key product developments include FDA approval for TAUKLARIFY and BRAVNETSA, CMS payment status for PYLARIFY TruVu, and the initiation of the SPARROW study for LNTH-2401.
PYLARIFY sales decreased 0.7% to $238.9 million, while Neuraceq sales surged 123.0% to $45.6 million and DEFINITY sales rose 4.8% to $85.7 million.